{
    "nctId": "NCT00445458",
    "briefTitle": "A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer",
    "officialTitle": "A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel",
    "eligibilityCriteria": "Inclusion Criteria:\n\nInclusion criteria for both parts of clinical trial:\n\n* Good performance status\n* Normal ejection fraction\n* Adequate cardiac, kidney, and liver function\n* Adequate blood counts\n* At least one measurable target lesion\n* Negative pregnancy test for female subjects\n\nInclusion Criteria for Part 1 Only:\n\n- Pathologically confirmed solid tumor not curable with available standard therapy\n\nInclusion Criteria for Part 2 Only:\n\n* Pathologically confirmed breast cancer\n* HER2 positive tumor\n* Prior treatment with Herceptin\n\nExclusion Criteria:\n\nExclusion criteria for both parts of clinical trial:\n\n* Major surgery, radiotherapy, chemotherapy or investigational agents within two weeks of treatment day 1\n* Subjects with bone or skin as the only site of disease\n* Active central nervous system metastases\n* Significant cardiac disease or dysfunction\n* Significant gastrointestinal disorder\n* Inability or unwillingness to swallow HKI-272 capsules\n* Prior exposure to HKI-272 or other HER2 targeted agents, except trastuzumab (Part 2 only). Prior lapatinib is permitted in arm B of part 2.\n* Treatment with a taxane within 3 months of treatment day 1\n* Grade 2 or greater motor or sensory neuropathy\n* Pregnant or breast feeding women\n* Known hypersensitivity to paclitaxel or Cremophor EL\n* Prior treatment with anthracyclines with cumulative dose of \\>400 mg/m\\^2\n* Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin\n\nExclusion Criteria for Part 2 Only:\n\n- More than 1 (arm A) or 3 (arm B) prior cytotoxic chemotherapy regimen for metastatic disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}